PFE’s 7.27% yield looks safe on a 53% adjusted payout ratio, but free cash flow fell short of dividends paid in 2025 by $690 million. <\/p>\n<\/li>\n
Eleven directors acquired PFE phantom stock at $26.67 on the same day, and CEO Albert Bourla bought shares six times in three months. <\/p>\n<\/li>\n
Pfizer’s 3.26x net debt-to-EBITDA from the Seagen deal makes its $7.2 billion cost savings target critical to keeping the dividend intact. <\/p>\n<\/li>\n
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Pfizer didn’t make the cut. Grab the names FREE today<\/a>. <\/p>\n<\/li>\n<\/ul>\n Few large-cap dividends generate as much skepticism as Pfizer<\/strong> (NYSE:PFE<\/a>). The stock trades at $24.37, and the COVID franchise erosion has been brutal, with Comirnaty down 59% and Paxlovid down 63% in Q1 2026. Yet the dividend keeps coming. I want to know if that 7.27% yield is a gift or a warning. <\/p>\n Pfizer’s foundational portfolio in oncology, immunology, and cardiovascular care generates non-discretionary demand, and management recently declared its 351st consecutive quarterly payout. <\/p>\n Cash Flow Covers the Dividend, but Just Barely <\/p>\n This is where I get cautious. In 2025, operating cash flow was $11.71 billion and capex was $2.63 billion, leaving free cash flow of $9.08 billion against $9.77 billion in dividends paid. On adjusted earnings, however, the math looks better: full-year adjusted EPS of $3.22 against $1.72 in dividends works out to a 53% payout. <\/p>\n Leverage Is the Real Pressure Point <\/p>\n Pfizer carries the Seagen acquisition debt, and it shows. Net debt-to-EBITDA sits at 3.26x, elevated for a pharma major, while interest coverage of 5.78x and debt-to-equity of 0.78 leave room to service obligations. The $7.2 billion cost savings target by end of 2027 matters because it directly defends the payout. <\/p>\n Act now:<\/strong> the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Pfizer didn’t make the cut. Grab the names FREE today<\/a>. <\/p>\n A Streak Reset by 2009, Rebuilt Since <\/p>\n Pfizer cut from $0.32 to $0.16 quarterly in 2009 to fund the Wyeth deal. Since 2010, the dividend has climbed every year, but recent raises are minimal. <\/p>\n Management and Insiders Are Putting Money Where the Mouth Is <\/p>\n CEO Albert Bourla told investors in Q1 2026: “We’re off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer.” Backing that up, 11 directors simultaneously acquired phantom stock units on April 23, 2026 at $26.67 per share, and Bourla himself added six times in three months. <\/p>\n Verdict: Safe, but Watch the Cash Conversion <\/p>\n Dividend Safety Rating: Safe.<\/strong> The earnings payout near 53% is comfortable, growth products like Eliquis, Padcev (+39%), and Vyndaqel (+8%) are scaling, and the Vyndamax patent now runs to June 2031. Pfizer fits an income-oriented thesis if the non-COVID portfolio offsets the $1.5 billion biosimilar headwind. The safety case weakens if FCF coverage stays under 1.0x for another full year, because management cannot lean on the balance sheet forever. <\/p>\n Act now:<\/strong> the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Pfizer didn’t make the cut. Grab the names FREE today<\/a>. <\/p>\n<\/a> PeopleImages \/ Getty Images The Dividend at a Glance <\/p>\n